Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based
pharmaceutical company currently in the preclinical stage, dedicated to
developing and commercializing therapeutic projects and diagnostic
technologies to tackle unmet medical needs, today announced that on
December 3, 2018, its registration statement on Form F-1, relating to a
proposed initial public offering (“IPO” or the “Offering”) of its Class
A Ordinary Shares, par value US$1.00 per share (the “Shares”), at a
price to the public of $15.80 per share, for gross proceeds of a minimum
of US$10 million and up to US$30 million, has been declared effective by
the U.S. Securities and Exchange Commission (“SEC”). The Company is
offering up to 1,898,734 Shares and up to 51,990 underwriter warrants
while certain selling shareholders are offering up to 1,595,235 Shares
(collectively, the “Registered Securities”). None of the gross proceeds
will be used to purchase the selling shareholders’ securities. The
Shares are expected to begin trading on The NASDAQ Global Market
on December 18, 2018, under the symbol APM. This Offering is expected to
close on or before December 12, 2018, subject to customary closing
conditions.…
続きを読む
